
|Videos|January 16, 2014
Emerging Treatment Options for Patients With Kidney Cancer
Author(s)James J. Hsieh, MD, PhD
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
Advertisement
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
- New emerging treatment options are all trial-based
- There are newer antiangiogenic agents that are just as efficacious but generate less toxicity
- Researchers and oncologists are excited about immunotherapy for the treatment of kidney cancer
- New immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















